Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 5 of 5 for “"KRAS oncogene"”.
-
Differential Activity of The Kras Oncogene By Method of Activation: Implications For Signaling and Therapeutic Intervention
… predicting for resistance to therapy, the <em>KRAS</em> oncogene remains a target in cancer for which there is no effective treatment. KRas is activated b y mutations at a few sites, primarily amino acid substitutions at codon 12 which promote a constitutively active state. I have found that …
-
Investigating the requirement of KRAS for the maintenance of pancreatic cancer
… studies have identified mutations in the proto-oncogene KRAS as a hallmark of PDAC, making KRAS an attractive therapeutic target. While the driver role of oncogenic KRAS for PDAC initiation has been well established, the degree of KRAS oncogene addiction in established PDAC tumors remains …
-
Biomimetic platforms for modeling in vitro the functional unit of the exocrine pancreas
… with epithelial cells overexpressing the KRAS oncogene which are also reported in vivo. • The information acquired using this simplified model were then transferred to a more complex 2.5D model, represented by a multilayer PDAC-on-chip system. This microfluidic device was designed to …
-
Ο ρόλος του επιθηλιακού πυρηνικού παράγοντα -κΒ στη χημική και γενετική καρκινογένεση πνεύμονα
… αναπνευστικής επιθηλιακής έκφρασης ογκογόνου KRASG12D. . Για το σκοπό αυτό, ιχνηλατήσαμε την ενεργότητα του NF-κΒ στους πνεύμονες κατά τη διάρκεια γενετικά επαγόμενης καρκινογένεσης και βρήκαμε δύο διακριτές πρώιμες και όψιμες φάσεις ενεργοποίησής του, οι οποίες χαρακτηρίζονται από πυρηνική …
-
TARGETING CANCER METABOLISM WITH FASTING-MIMICKING DIET¿BASED LOW-TOXIC COMBINATION THERAPIES: OVERCOMING RESISTANCE THROUGH METABOLIC SYNERGY
… (NSCLC) is the most prevalent and lethal, with KRAS mutations occurring in up to 25–30% of lung adenocarcinomas. Tumors harbouring this mutated oncogene are particularly resistant to targeted therapies, highlighting the need for novel targeted low-toxicity strategies. Nutrient restriction …